Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) Clinical Trials

8 clinical trials for Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) — RECRUITING · PHASE1
• Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors — RECRUITING · PHASE1
• Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine Carcinoma — RECRUITING · PHASE2
• Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease — NOT_YET_RECRUITING · PHASE1
• Iparomlimab and Tuvonralimab (QL1706) Plus Lenvatinib and Chemotherapy for Extrapulmonary Neuroendocrine Carcinoma — NOT_YET_RECRUITING · PHASE2
• A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1) — NOT_YET_RECRUITING · PHASE1
• Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer — WITHDRAWN · PHASE1
• A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC — NOT_YET_RECRUITING · PHASE2

Refine this search